Glucose-responsive insulin-delivery platforms that are sensitive to dynamic glucose concentration fluctuations and provide both rapid and prolonged insulin release have great potential to control hyperglycemia and avoid hypoglycemia diabetes. Here, biodegradable and charge-switchable phytoglycogen nanoparticles capable of glucose-stimulated insulin release are engineered. The nanoparticles are “nanosugars” bearing glucose-sensitive phenylboronic acid groups and amine moieties that allow effective complexation with insulin (≈95% loading capacity) to form nanocomplexes. A single subcutaneous injection of nanocomplexes shows a rapid and efficient response to a glucose challenge in two distinct diabetic mouse models, resulting in optimal blood ...
Diabetes mellitus, a disorder of glucose regulation, is a global burden affecting 366 million people...
Insulin administration mimicking physiological insulin secretion behavior remains a challenge for th...
The management of diabetes in a manner offering autonomous insulin therapy responsive to glucose-dir...
Glucose-responsive insulin-delivery platforms that are sensitive to dynamic glucose concentration fl...
Glucose-responsive insulin-delivery platforms that are sensitive to dynamic glucose concentration fl...
Copyright © 2019 American Chemical Society. To mimic native insulin activity, materials have been de...
ABSTRACT: A new glucose-responsive formulation for self-regulated insulin delivery was constructed b...
A new glucose-responsive formulation for self-regulated insulin delivery was constructed by packing ...
An insulin delivery system that self-regulates blood glucose levels has the potential to limit hypog...
A new glucose-responsive formulation for self-regulated insulin delivery was constructed by packing ...
Diabetes mellitus, a disorder of glucose regulation, is a global burden affecting 366 million people...
Insulin administration mimicking physiological insulin secretion behavior remains a challenge for th...
Diabetes mellitus, a disorder of glucose regulation, is a global burden affecting 366 million people...
Diabetes mellitus, a disorder of glucose regulation, is a global burden affecting 366 million people...
Diabetes mellitus, a disorder of glucose regulation, is a global burden affecting 366 million people...
Diabetes mellitus, a disorder of glucose regulation, is a global burden affecting 366 million people...
Insulin administration mimicking physiological insulin secretion behavior remains a challenge for th...
The management of diabetes in a manner offering autonomous insulin therapy responsive to glucose-dir...
Glucose-responsive insulin-delivery platforms that are sensitive to dynamic glucose concentration fl...
Glucose-responsive insulin-delivery platforms that are sensitive to dynamic glucose concentration fl...
Copyright © 2019 American Chemical Society. To mimic native insulin activity, materials have been de...
ABSTRACT: A new glucose-responsive formulation for self-regulated insulin delivery was constructed b...
A new glucose-responsive formulation for self-regulated insulin delivery was constructed by packing ...
An insulin delivery system that self-regulates blood glucose levels has the potential to limit hypog...
A new glucose-responsive formulation for self-regulated insulin delivery was constructed by packing ...
Diabetes mellitus, a disorder of glucose regulation, is a global burden affecting 366 million people...
Insulin administration mimicking physiological insulin secretion behavior remains a challenge for th...
Diabetes mellitus, a disorder of glucose regulation, is a global burden affecting 366 million people...
Diabetes mellitus, a disorder of glucose regulation, is a global burden affecting 366 million people...
Diabetes mellitus, a disorder of glucose regulation, is a global burden affecting 366 million people...
Diabetes mellitus, a disorder of glucose regulation, is a global burden affecting 366 million people...
Insulin administration mimicking physiological insulin secretion behavior remains a challenge for th...
The management of diabetes in a manner offering autonomous insulin therapy responsive to glucose-dir...